登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《MedRxiv，4月20日，（第2版更新）Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: A multicenter retrospective cohort study》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-04-21

  • Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: A multicenter retrospective cohort study

    Ziyun Shao Sr., Yongwen Feng, Li Zhong, Qifeng Xie, Ming Lei, Zheying Liu, Conglin Wang, Jingjing Ji, Huiheng Liu, Zhengtao Gu, Zhongwei Hu, Lei Su, Min Wu, Zhifeng Liu

    doi: https://doi.org/10.1101/2020.04.11.20061739

    Abstract

    Importance: Coronavirus disease 2019 (COVID-19) has become pandemic, causing more than 1.5 million infections and over ten-thousands of deaths in a short period of time worldwide. However, little is known about its pathological mechanism, and reports on clinical study on specific treatment are few. Objective: The purpose of this study is to determine the clinical efficacy of intravenous immunoglobulin (IVIG) therapy in COVID-19 patients. Design, setting and participants: This multicenter retrospective cohort study enrolled 325 adult critical COVID-19 patients, including severe type and critical type, according to the clinical classification defined by National Health Commission of China, in 8 government designated treatment centers in China from Dec 23, 2019 to Mar 31, 2020. Demographic, clinical, treatment, and laboratory data as well as prognosis were extracted from electronic medical records.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.medrxiv.org/content/10.1101/2020.04.11.20061739v2
123浏览量
原文链接
相关报告

  • 《MedRxiv，4月20日，（第2版更新）Links between air pollution and COVID-19 in England》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-21
    • Links between air pollution and COVID-19 in England View ORCID ProfileMarco Travaglio, View ORCID ProfileRebeka Popovic, View ORCID ProfileYizhou Yu, View ORCID ProfileNuno Leal, View ORCID ProfileL. Miguel Martins doi: https://doi.org/10.1101/2020.04.16.20067405 Abstract In December 2019 a novel disease [coronavirus disease 19 (COVID-19) emerged in the Wuhan province of the People's Republic of China. COVID-19 is caused by a novel coronavirus (SARS-CoV-2) thought to have jumped species, from another mammal to humans. A pandemic caused by this virus is running rampant throughout the world. Thousands of cases of COVID-19 are reported in England and over 10,000 patients have died. Whilst there has been progress in managing this disease, it is not clear which factors, besides age, affect the severity and mortality of COVID-19. A recent analysis of COVID-19 in Italy identified links between air pollution and death rates. Here, we explored the correlation between three major air pollutants linked to fossil fuels and SARS-CoV-2 lethality in England. We compare up-to-date, real-time SARS-CoV-2 cases and death measurements from public databases to air pollution data monitored across over 120 sites in different regions. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    147浏览量
    原文链接

  • 《Lancet，6月24日，Tocilizumab in patients with severe COVID-19: a retrospective cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-06-26
    • Tocilizumab in patients with severe COVID-19: a retrospective cohort study Prof Giovanni Guaraldi, MD † Marianna Meschiari, MD † Prof Alessandro Cozzi-Lepri, PhD Jovana Milic, MD Roberto Tonelli, MD Marianna Menozzi, MD Published:June 24, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30173-9 Summary Background No therapy is approved for COVID-19 pneumonia. The aim of this study was to assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and death in patients with severe COVID-19 pneumonia who received standard of care treatment. Methods This retrospective, observational cohort study included adults (≥18 years) with severe COVID-19 pneumonia who were admitted to tertiary care centres in Bologna and Reggio Emilia, Italy, between Feb 21 and March 24, 2020, and a tertiary care centre in Modena, Italy, between Feb 21 and April 30, 2020. All patients were treated with the standard of care (ie, supplemental oxygen, hydroxychloroquine, azithromycin, antiretrovirals, and low molecular weight heparin), and a non-randomly selected subset of patients also received tocilizumab. Tocilizumab was given either intravenously at 8 mg/kg bodyweight (up to a maximum of 800 mg) in two infusions, 12 h apart, or subcutaneously at 162 mg administered in two simultaneous doses, one in each thigh (ie, 324 mg in total), when the intravenous formulation was unavailable.
    190浏览量
    原文链接